01/03Milestone
A decade of backing biotech innovation
Since 2016, Taiho Ventures has invested in more than 30 companies developing novel therapeutics — with multiple public listings and acquisitions by Johnson & Johnson, Eli Lilly, and Sanofi.
02/03Portfolio
Arcus Biosciences: where it began
Our first portfolio company is now a public oncology innovator (NYSE: RCUS) — and granted Taiho exclusive licenses to five pipeline programs.
On the cap table since 201603/03Portfolio
Halda Therapeutics: a $3.05B exit
Halda's first-in-class RIPTAC platform for precision oncology was acquired by Johnson & Johnson for $3.05 billion.
Acquired by Johnson & Johnson · 2026Who we are
Taiho Ventures is the corporate venture arm of Taiho Pharmaceutical Co., Ltd. Since 2016, we have invested in more than 30 early-stage private companies strategically relevant to Taiho Pharmaceutical.
Learn more about us →
Why partner with us
What we bring
Patient, long-term capital.
Our evergreen fund structure lets us support portfolio companies beyond the limits of a traditional fund life cycle.
A strategic partner, not just a check.
We invest where the science is relevant to Taiho's R&D — and we can open the door to it. Our first portfolio company, Arcus Biosciences, granted Taiho exclusive licenses to five of its pipeline programs.
Flexible structures.
We consider company creation, spin-outs, and option-type investments as well as pure equity investments.
A proven track record.
Our portfolio has produced public listings and acquisitions by Johnson & Johnson, Eli Lilly, Sanofi, and Merck.
What we look for
We back companies whose science is strategically relevant to Taiho Pharmaceutical, primarily at the research-to-pre-IND stage (IND-to-proof-of-concept considered opportunistically).
Drug discovery (first-in-class or new-biology approaches), innovative drug-discovery platforms, spin-outs from Taiho pipelines, and — opportunistically — medical device, diagnostics, and digital health.
Oncology, and non-oncology (immunology, allergy, bone, muscle, orphan).
Small molecules, biologics, and gene/cell therapy.
United States, Europe, and Japan.
Selected portfolio outcomes
Since 2016 we have backed more than 30 companies. Our portfolio has produced multiple public listings and acquisitions by leading pharmaceutical companies.
Public listings
- Arcus Biosciences
- ORIC Pharmaceuticals
- Werewolf Therapeutics
Acquisitions
- Harpoon TherapeuticsMerck
- Halda TherapeuticsJohnson & Johnson
- Orna TherapeuticsEli Lilly
- Dren BioSanofi · lead asset
For founders
If your company fits the focus above and is based in the U.S., Europe, or Japan, we'd like to hear from you.
Taiho Ventures, LLC2420 Sand Hill Road, Suite 203Menlo Park, CA 94025-6940